February 11, 2020 / 9:29 PM / 11 days ago

Australia's CSL posts 8% rise in H1 profit; raises FY outlook

Feb 12 (Reuters) - Australian biotech company CSL Ltd on Wednesday posted an 8% rise in first-half profit and raised its earnings forecast for the full year, helped by strong demand for its immunoglobulin (IG) products.

The company, which makes treatments for blood-related diseases and vaccines for influenza, posted a net profit of $1.25 billion for the six months ended Dec. 31, compared with $1.16 billion a year earlier.

CSL raised its after-tax net profit forecast for the full year to a range of $2.11 billion to $2.17 billion at constant currency. (Reporting by Shreya Mariam Job and Nikhil Subba in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below